Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. - Test2 - elhamkhani - TriplyDB

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

http://www.wikidata.org/entity/Q38816272

about

Does early resection of presumed low-grade glioma improve survival? A clinical perspective.Controversies in management of low-grade gliomas in light of new data from clinical trials.Immunotherapy and radiation in glioblastoma.Advances in the molecular genetics of gliomas - implications for classification and therapy.Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma.Milestones of the last 10 years: CNS cancer Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies.Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.Molecular profiling optimizes the treatment of low-grade glioma.Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016.Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases.Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high-risk grade 2 glioma: An analysis of the National Cancer Data Base.Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy.SSRP1 silencing inhibits the proliferation and malignancy of human glioma cells via the MAPK signaling pathway.The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.SEOM clinical guideline of diagnosis and management of low-grade glioma (2017).Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.Neuro-oncology in 2016: Advances in brain tumour classification and therapy.IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy.Current therapeutic approaches to diffuse grade II and III gliomas.SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis.Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience.Retrospective assessment of MRI-based volumetric changes of normal tissues in glioma patients following radio(chemo)therapy.Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.A trend towards a more intense adjuvant treatment of low-grade-gliomas in tertiary centers in Germany after RTOG 9802 - results from a multi-center survey Comprehensive evaluation of treatment and outcomes of low-grade diffuse gliomas Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review

P2860

Q33867304-9AD463A5-65D6-443F-B7CA-B2DD91448907 Q36341111-66E31933-E18B-453E-9A33-95D662C5158B Q38752191-82C73C70-B78D-4C76-A67A-7CD68BBEA345 Q38777058-7183CBC4-ECB6-48F9-8DD8-C28626F1697D Q38825570-2972420E-A0D1-4154-9326-0A25FB8F6E1B Q38861548-DA0CB29F-A7C9-4395-8FEB-611F7447C698 Q39159242-259DC370-4C61-4129-8B27-DE39FDCB11DF Q39301977-ABAB4C24-EB08-40A9-8163-EF55779165C5 Q45047654-B0755155-4862-4656-8CE4-CA3422574E2F Q47133444-BACCA6A9-68E4-4A1F-A128-1451EC17B437 Q47139133-FD243E58-0A33-48F3-9697-4F141241B6A8 Q47142436-682CE747-48CF-4F64-B77E-909CA0C5A7B8 Q47368483-3C6BD06C-3D1F-4F76-B9C1-B826C4D81D09 Q47369186-7D381962-018D-415B-96E8-9B14670478B1 Q47577963-36FB1E8B-7177-4509-8E0D-CB2065D46034 Q47629853-7DED4A96-E905-472A-81D6-11474859D872 Q47827411-96879D5C-68E0-4CC3-A843-DC5D96A5E87D Q47840899-98CD4C46-F157-46E8-A1A8-87CBBF498C80 Q47976126-FD695F58-9BC2-4E01-A135-F106164FB4B3 Q48157598-C0A85E50-F8CF-4C5E-900E-F60C779758A3 Q48295109-CD2E7315-F70E-4357-B252-6FF4F317B5F5 Q48348431-AC23F2D5-47C1-48E7-940A-FBA158F8AADD Q48663479-2FD38BF6-369F-45C2-9E59-46B5B84A5684 Q49317056-93809473-DAA7-4CDE-BD47-9E91C56650F7 Q49893500-C051A407-8D03-4CDE-93C1-936D28573BD7 Q50654475-A160336E-F1B4-4877-BB01-A5B571860D00 Q51733040-7DB2A600-5DF8-4095-89E9-4BA51917B09A Q52682578-2EA8354A-214E-400A-9D65-80808CC0C06E Q53098438-3CA919E7-04C2-4575-AE4D-BD33A2845023 Q55456723-4E3716A1-58BE-48FF-8D18-6992162EB36F Q58706639-99F6AC33-81BB-4815-A1BB-D70AF14E5B6B Q58713653-1FF171E5-6F72-47B9-A8BE-E636BFE4CAFA Q58739882-A31DB96B-E5B5-461F-B9BC-E6101C17B026

P2860

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

http://www.wikidata.org/entity/Q38816272

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Temozolomide chemotherapy vers ...... bel, phase 3 intergroup study.

@en

type

label

Temozolomide chemotherapy vers ...... bel, phase 3 intergroup study.

@en

prefLabel

Temozolomide chemotherapy vers ...... bel, phase 3 intergroup study.

@en

P1433

Q38816272-98E5B902-33A6-4E48-A06B-D5C19E0EB57C

P1476

Q38816272-0A8720AA-606C-43B2-B336-005EDC0335F4

P2093

Q38816272-0737FFFC-5B8D-4605-BB77-AF7193521A8B

Q38816272-0CA7251E-1535-4640-8202-7098D64792A7

Q38816272-114C618A-A445-4396-8DCE-92821AD52D1C

Q38816272-3AEAED8A-228B-4C92-A58E-AE16365D2772

Q38816272-3F101C86-DE43-4009-95D9-6AA404F39C38

Q38816272-4D86DD51-6F83-43DA-B893-7EB3E6ECC7A5

Q38816272-510DB63E-D9F8-44CE-81FB-24C4D545CE83

Q38816272-5BB2C3A6-AA4A-41B7-811B-15D5E815AEDC

Q38816272-61EA1190-F8BD-454D-8BD6-E970DBCCEF85

Q38816272-6BF6D13C-648D-470B-8732-DEFAF49F94E8

P2860

Q38816272-038B8770-7849-4275-9909-776F6DA79612

Q38816272-077D92B6-8CCD-4C0C-88C3-F690C46DC499

Q38816272-0881C06C-66C5-4678-9A91-5107E81951F8

Q38816272-154C5664-EEE9-4598-AC4D-EAFEAFDFE01C

Q38816272-16973A7C-66FD-49D1-9A44-05EC427C9D22

Q38816272-17B8ACCD-523E-4B0F-A9C4-F4A593BAFA54

Q38816272-188C83BF-38A5-4D76-92FF-E3C925662423

Q38816272-2F50CAD1-AAA0-4D02-8234-0A60AEEC7E31

Q38816272-31FCB33D-D9CD-4D76-95FB-2EF558708FA1

Q38816272-32714D1A-526A-4CE8-8383-B9BFE0013127

P304

Q38816272-A0BC7AA2-B64E-48C8-8664-03201C0CEE0F

P31

Q38816272-2AE7AD60-3779-46E2-BEF6-F50727DEFCCA

P356

Q38816272-C726F06F-FAA4-4309-8D25-76CA485891A0

P433

Q38816272-B0F8B4AD-02FB-4EA8-81A4-444A8D2AA543

P478

Q38816272-FF876C6A-DE5C-4BCE-97D1-54E67BD10A44

P50

Q38816272-0905C1AC-899D-4ECC-9807-F3B52574D663

Q38816272-0DAD47CD-939B-4EB9-9B8C-0E88580F41BA

Q38816272-29B75A48-125A-46ED-96D7-8EAFDF3A276F

Q38816272-76D0725E-5E0F-4B4D-9268-B01F0CF4A4EE

Q38816272-C098CC6A-D020-4DC0-B807-F9507FE8E065

Q38816272-E1E6426D-2D63-4AAE-B655-27F449B6F885

P577

Q38816272-2E20BA0A-00E3-4840-9F4B-3EEF47382138

P698

Q38816272-2360B9E8-C438-4942-9BE2-4B79D8DDBF7C

P921

Q38816272-24907CBE-D52B-4168-9B57-A9ABCCCB54F8

Q38816272-893CBF0D-6663-4892-B468-3551827A1DA1

P932

Q38816272-1DCDB684-B03F-4317-BBA2-0C5767EA5980

P356

S1470-2045(16)30313-8

P1433

The Lancet Oncology

P1476

Temozolomide chemotherapy vers ...... bel, phase 3 intergroup study.

@en

P2093

Alba A Brandes

http://www.w3.org/2001/XMLSchema#string

Brian Thiessen

http://www.w3.org/2001/XMLSchema#string

Brigitta G Baumert

http://www.w3.org/2001/XMLSchema#string

Carmen Balana

http://www.w3.org/2001/XMLSchema#string

Christian Hartmann

http://www.w3.org/2001/XMLSchema#string

Christine Marosi

http://www.w3.org/2001/XMLSchema#string

Denis Lacombe

http://www.w3.org/2001/XMLSchema#string

Frederic Dhermain

http://www.w3.org/2001/XMLSchema#string

Gail Ryan

http://www.w3.org/2001/XMLSchema#string

Guy Kantor

http://www.w3.org/2001/XMLSchema#string

P2860

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.

Phase II trial of temozolomide in patients with progressive low-grade glioma.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.

Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas.

P304

1521-1532

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(16)30313-8

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Andreas von Deimling

Sebastian Kurscheid

P577

2016-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27686946

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

5124485

http://www.w3.org/2001/XMLSchema#string